Tag: Proteomics International Laboratories

Biomarker, Innovation

Proteomics secures licence to commercialise QIMR’s cancer biomarkers

June 21, 2022


Proteomics International Laboratories has secured a worldwide licence to commercialise QIMR Berghofer Medical Research Institute’s oesophageal cancer biomarkers. The new collaboration is intended to improve the detection of oesophageal adenocarcinoma, which is the most common form of oesophageal cancer. Under […]